Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic Neoplasms
LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)-- Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today the launch of a newly established next generation sequencing service at the Summit Health laboratory in Woodland Park, NJ to offer comprehensive DNA and RNA profiling of solid tumors and hematologic neoplasms. The internalized GTC testing menu includes tissue and bone marrow-based DNA and RNA next generation sequencing of hematologic neoplasms and solid tumors. Summit Health will now offer GTC's peripheral blood and CSF-based liquid biopsy, Liquid Trace. This revolutionary liquid biopsy assay analyzes cell free DNA and RNA (cfDNA and cfRNA) for hematologic neoplasms and solid tumors. This testing provides Summit/Village MD clinicians with a comprehensive precision diagnosis and monitoring tools to deliver state-of-the-art precision care for their patients. By running the tests locally in-house, Summit Health will reduce their send-out burden to multiple labs, standardize collection of data, shorten turn-around time and have the opportunity to participate in R&D, clinical trials and the development of IP.
As a member of the GTC Co-Op group, Summit Health will gain access to cutting-edge scientific capabilities, access to a pipeline of innovation in diagnostics, and proprietary technology and datasets for R&D.
"We are very thrilled to partner with GTC in internalizing and adopting their comprehensive portfolio of tissue and liquid biopsy tests for hematologic neoplasms and solid tumors. We believe that this testing is currently essential for the practice of precision medicine,' said Dr. Gordana Katava, DO, Chief of Pathology and Laboratory Medicine, Summit Health/Village MD.
Dr. Maher Albitar, Founder, CEO and Chief Medical Officer at GTC, stated, 'We are excited to add Summit and Village MD physicians to our Co-Op network. GTC was established on the promise of democratizing genomic science and next generation sequencing. This partnership is a step forward toward achieving our goal,' Dr. Albitar added. 'The Co-OP model is not only standardizing next generation sequencing, but also providing ecosystem for cooperation, sharing knowledge and AI-based software, and reducing cost of internalizing NGS.'
About Summit Health
Summit Health, which is a part of VillageMD, helps patients with all their comprehensive primary care and multi-specialty care needs. Whether it's getting annual checkups, raising a family, or prioritizing healthy aging, Summit Health works as a team to deliver care that helps patients make the right choices and stay a step ahead of any issues. Summit Health offers high-quality connected care services covering nearly every medical specialty including orthopedics, urology, dermatology, cardiology, gastroenterology, and more. When patients need urgent care, they can visit Summit Health's urgent care partner, CityMD, which has 180+ locations throughout N.Y. and N.J. Together, Summit Health and CityMD are one connected care team.
About GTC
Genomic Testing Cooperative [GTC], the global leader in RNA innovation, is a privately owned molecular testing company located in Lake Forest, California. Since its inception in 2018 GTC has been focused on facilitating the acceleration of access to NGS enabled precision medicine in Oncology through innovative science and differentiated business models and practices and has grown through the realization of these strategies to become a leading partner/provider in the Oncology NGS space helping healthcare organizations to tackle the biggest problems in Next Generation Sequencing for Oncology today.
Forward Looking Statements
All the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on GTC and Summit Health management's current expectations and include statements regarding the value of Molecular profiling, testing, therapy, and the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and Summit Health or GTC undertake no duty to update this information unless required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a day ago
- CNBC
Why the stock rally fizzled — plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks rose modestly Thursday but were well off their highest levels of the session. The strong quarter from Club name Nvidia is lifting the broader artificial intelligence trade. As we explained in our earnings commentary Wednesday night, four positive developments have gone Nvidia's way since its annual GTC event in March, fueling additional momentum in its business. The market also got a brief boost after the U.S. Court of International Trade ruled President Donald Trump doesn't have the authority to impose "reciprocal" tariffs on virtually every nation. However, the path forward for this case is unclear, which is why the market's initial gains on the news didn't last. The Trump administration plans to take the case to the Supreme Court on Friday. Tariffs can still be imposed through alternative ways. For example, sector-specific tariffs remain an option, and the president can still invoke Section 232 to impose trade restrictions on the grounds of national security. Bank update: Goldman Sachs President and Chief Operating Officer John Waldron spoke at the Bernstein Strategic Decision Conference on Thursday. Shares were down on the session, underperforming the broader financial sector. The line that may have hit the stock was Waldron explaining that investment banking activity in the second quarter has not been as strong as in the first quarter. It's hard to get deals over the finish line in a highly volatile, uncertain environment like the market dealt with in April. "When you have this kind of volatility, you just fundamentally have a harder time prosecuting transactions that may be in your pipeline, but they don't happen as quickly as you might otherwise expect," Waldron said at the conference. Nobody should have been surprised by Waldron's comments. Peers have said similar things. For example, on May 19, we pointed out that JPMorgan said it expected investment banking fees in the second quarter to be down by a mid-teen percentage year over year. There are two other things to keep in mind: While volatility is bad for mergers-and-acquisition activity, as well as initial public offerings, it is a great thing for Goldman's trading desk. Waldron said Thursday that equity trading client activity has "remained robust" throughout the year, though levels for fixed income, currencies, and commodities (FICC) are now "slightly softer" than the company's strong results this time last year. FICC revenue increased 17% year-over-year in the second quarter of 2024. There has also been a significant pickup in capital markets activity over the past few weeks. We recently highlighted fresh signs of life in the initial public offering (IPO) market. More companies are filing to go public, including Omada Health, expected next week , targeting a market cap of slightly more than $1 billion. Goldman is involved in the Omada deal. This follows last week's IPOs of Hinge Health and MNTN . We're also starting to see more mergers and acquisitions (M & A), with a notable one this week from Club name Salesforce , which agreed to buy Informatica for $8 billion. With one month remaining in the second quarter, we expect muted investment bank fee growth when the banks report earnings in mid-July. However, a stronger second half for Goldman Sachs should be in store, provided the current pause in high tariffs remains in place. Cobenfy comments: Bristol Myers Squibb CEO Chris Boerner tried to assuage investor concerns about the company's key schizophrenia drug, Cobenfy, on Thursday. During the Wall Street Journal's Future of Everything conference, Boerner came to Cobenfy's defense after it failed a key late-stage trial in April that evaluated how it worked when used as an add-on treatment. He argued Thursday that the results "don't have really any impact on the long-term potential" of Cobenfy, explaining the focus has always been to use the drug as a primary treatment. "What we like about Cobenfy is we're seeing efficacy on par with, if not better than, all the existing therapies, but without some of the really onerous side effects," Boerner added, citing impacts from other treatments like significant weight gain. While this was welcomed commentary, the company argued a similar case when it reported earnings in late April. The surprising adjunctive trial result turned what we thought was a straightforward story of a drug with underappreciated potential into a more complicated "show me" situation. And what we need to be shown is better Cobenfy data in future trial readouts. That's why we haven't bought back any of the stock we sold in the low $60s a share earlier this year, as Jim Cramer explained on the Monthly Meeting last week. The stock was up about 1% to around $47 per share Thursday. Asked about the potential for pharmaceutical-specific tariffs, Boerner said that Bristol Myers would prefer the Trump administration take a different direction. But he added he's tried to communicate ways to "do it without messing things up." Whatever the Trump administration does, they have to recognize the "reality of the dynamics of biopharmaceutical manufacturing," he offered. "If you don't get that right, you will end up with supply constraints, and that's something nobody wants, including the administration. Incidentally, it's also why typically when you've had tariffs, pharmaceutical and biotech products have been excluded." Up next: It's another big night of earnings ahead with Club name Costco , Marvell Technology and Dell Technologies scheduled to report. Other companies reporting are Gap , American Eagle Outfitters , Ulta Beauty and Zscaler . There are no major earnings reports after Friday's close. On the data side Friday morning, we get the Federal Reserve's preferred inflation gauge — the personal consumption expenditures price (PCE) index. According to FactSet, PCE is expected to have risen 0.15% month over month in April and 0.12% on a core basis, which excludes volatile food and energy prices. That would mean increases in the headline index and the core of 2.5% and 2.2% year over year, respectively, marking slightly cooler readings than in March. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
a day ago
- Yahoo
Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR
DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- The global Electronic Lab Notebook Market, valued at US$0.68 billion in 2024 stood at US$0.72 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$1.03 billion by the end of the period. The adoption of electronic lab notebooks (ELNs) is driven by the growing emphasis on laboratory digitization, the rising need for efficient data management, and integrated compatibility with advanced technologies. Additionally, the increasing use of ELNs within the life sciences sector is expected to fuel their adoption in the life sciences sector. The expanding role of biobanks is also contributing to this trend, as ELNs offer high efficiency in the storing & management of biobank data. As laboratories continue to automate, ELNs are increasingly replacing traditional paper-based notebooks. Download PDF Brochure: Browse in-depth TOC on "Electronic Lab Notebook Market" 110 - Tables40 - Figures200 - Pages By Based on organization size, the electronic lab notebook market has been segmented into small & medium and large organizations. In 2024, the large organization segment accounted for the largest share of the electronic lab notebook market. The key factors contributing to the growth of this segment include the expanding budgets for R&D activities, expanding healthcare infrastructure, and the rising need for robust & efficient data management systems to comply with stringent regulatory requirements. Large organizations often require ELNs that can integrate seamlessly with existing Laboratory Information Management Systems (LIMS), Electronic Lab Management Systems (ELMS), and other enterprise resource planning (ERP) systems. This integration is crucial for streamlining workflows and enhancing productivity. By end user, the ELN market is segmented into life sciences, agriculture and food & beverage, oil & gas and petrochemicals, chemical industry, environmental research, and other end users. The life sciences division is segmented into pharmaceutical & biotechnology companies, contract service organizations, biobanks & biorepositories, clinical research laboratories, academic research institutes, NGS laboratories, and toxicology laboratories. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the electronic lab notebook market. The rising demand for data reporting & management software within pharmaceutical & biopharmaceutical companies is a key factor contributing to the increasing adoption of electronic lab notebooks (ELNs). Additionally, the surge in R&D initiatives and the expansion of drug discovery & development activities has amplified the need for ELNs to streamline workflows, improve collaboration, and maintain compliance with regulatory requirements. By geography, the electronic lab notebook market is segmented into regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing reliance on companies in India & China to outsource drug development contract services; low manufacturing & labor costs; and the growing focus on lab automation and digitization. Supportive initiatives by the government & other private players in the market for expanding healthcare infrastructure are expected to also provide an impetus for adopting electronic lab notebooks during the forecast period. Request Sample Pages : The prominent players operating in the electronic lab notebook market include Revvity, Inc. (US), Dassault Systèmes (France), Benchling (US), Thermo Fisher Scientific, Inc. (US), Waters Corporation (US), IDBS (US), STARLIMS Corporation (US), LabVantage Solutions Inc. (US), LabLynx, Inc (US), Agilent Technologies, Inc. (US), LabWare (US), Eppendorf SE (Germany), Dotmatics (US), Lab-Ally (US), Labforward GmbH (Germany), and Labii Inc. (US), among others. These companies adopted product/service launches, enhancements, agreements, expansions, partnerships, collaborations, and acquisitions to strengthen their market presence in the electronic lab notebook market. Revvity, Inc (US): Revvity, Inc., is a leading provider of ELN solutions, experiencing consistent growth due to its unique and competitive offerings for customers across several industries. The company's leading cloud-native Electronic Lab Notebook (ELN) seamlessly facilitates collaboration and data capture technology. With integrated features such as ChemDraw and Spotfire, the company expedites innovation across various sectors, including Pharmaceutical & Biotechnology, Chemicals & Materials, and Food, Flavor, and Fragrance industries. Revvity designs future-proof solutions for enhanced collaboration & acceleration of scientific workflows, making it an essential tool across Biology, Chemistry, Formulations, and Analysis. In February 2022, Revvity (US) partnered with TetraScience (US). Through this collaboration, TetraScience provides users with the Revvity Signals Research Suite with vendor-agnostic, configurable, and productized instrument integrations via its Tetra R&D Data Cloud. This partnership aims to improve data interoperability and speed up scientific outcomes. Similar developments in the market are expected to offer the company an impetus for growth in the electronic lab notebook market. Dassault Systèmes (France) Dassault Systèmes provides software solutions & consulting services. Dassault Systèmes offers a comprehensive range of applications & solutions through the 3DEXPERIENCE platform. These tools support various domains such as analytics, design, engineering, manufacturing, scientific research, & supply chain planning. Dassault Systèmes has 290,000 customers and 25 million users across Africa, the Asia Pacific, Europe, Latin America, and North America. Dassault Systèmes has a diverse presence with over 180 offices in 42 countries, including the 3DS Paris Campus in France and the 3DS Boston Campus in the US. Thermo Fisher Scientific, Inc. (US) Thermo Fisher Scientific offers a range of Electronic Laboratory Notebook (ELN) solutions, including Labguru and Core ELN, to support research & data management. The company also integrates ELN functionalities into its broader suite of laboratory informatics solutions, including LIMS (Laboratory Information Management Systems) and data analysis tools. The ELNs Requests module is designed to meet the needs of quality control labs, contract research organizations, service labs, R&D, manufacturing, and logistics teams. Thermo Fisher Scientific focuses on providing customers with a complete, end-to-end solution for data acquisition, storage, and analysis. The company is actively working to integrate LIMS, CDS (Data Collection and Storage), and data interpretation tools onto a single platform using Microsoft technologies. The Labguru ELN module, for instance, enables seamless data exchange, traceability, and streamlined workflows. For more information, Inquire Now! Related Reports: Healthcare Cloud Computing Market Computer Vision in Healthcare Market Healthcare IT Market Healthcare Analytics Market Remote Patient Monitoring Market Get access to the latest updates on Electronic Lab Notebook Companies and Electronic Lab Notebook Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
a day ago
- Yahoo
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer. Following a joint Request for Proposals (RFP), 23 grant proposals were received from urology and urologic oncology institutions and organizations nationwide. After a rigorous review process, seven innovative projects were awarded grant funding, totaling $1.5 million on behalf of the Pfizer-Astellas Alliance. 'The AUA is proud to once again collaborate with Pfizer in supporting forward-thinking research and education in advanced prostate cancer,' said Mark Gonzalgo, MD, PhD, MBA, chair of education at the AUA. 'This grant initiative continues to foster groundbreaking strategies that address unmet needs in care delivery—from earlier diagnosis to individualized treatment approaches. We commend this year's grant recipients for their commitment to improving outcomes and elevating the standard of care for patients navigating this challenging disease.' Congratulations to the following selected applications: 'Addressing Genomic Disparities in Prostate Cancer: A Quality Improvement Initiative for Equitable Access to Germline and Somatic Testing' – Rohan Garje, MD, Miami Cancer Institute 'Advanced Prostate Cancer Collaboration Advances Rural Equity' – Charles Shelton, MD, The Outer Banks Hospital 'AI-Enhanced Quality Improvement to Optimize Genetic Testing in Advanced Prostate Cancer' – Kenneth Nepple, MD, University of Iowa 'Bridging Gaps in Advanced Prostate Cancer Care: A Quality Improvement Initiative in the Bronx' – Christopher Jakubowski, MD, Montefiore Medical Center 'Boosting Precision: Enhancing Germline and Somatic Testing in Advanced Prostate Cancer' – Guru Sonpavde, MD, AdventHealth Foundation Central Florida 'A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing' – Catherine Marshall, MD, MPH, Johns Hopkins University 'Implementing MyNavigator Platform in a High Volume, Rural Advanced Prostate Cancer Practice to Optimize Performance of Multidisciplinary Care Team, Improve Patient Symptom Monitoring, and Collect Real World Data: A Quality Improvement Initiative' – Timothy Richardson, MD, Avident Health, LLC *Pending executed agreements About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. CONTACT: Corey Del Bianco American Urological Association 443-689-4033 cdelbianco@
